Updated 23rd May 2022
This article was edited on 23rd May to avoid any implication that Luforbec is a low-carbon inhaler.
Following a third-party life-cycle assessment to quantify the carbon footprint of Luforbec 'from cradle to grave' - including its manufacture, distribution, use and disposal - the manufacturer Lupin Healthcare says it has offset the carbon emissions associated with the pressurised metered-dose inhaler (pMDI).
Further informationView Luforbec drug record
Luforbec, which is therapeutically equivalent to Fostair 100/6 pMDI, has a carbon footprint of 11.42–12.15kg CO2 equivalent per inhaler. Lupin Healthcare says it has invested in a renewable energy initiative, the Zhangbei Manjing Wind Farm near Beijing, to offset these emissions.
The Luforbec pMDI device is similar to the Fostair pMDI, providing 120 metered doses of 100 microgram beclometasone dipropionate and 6 microgram formoterol dihydrate. It includes a dose indicator and can be used with the AeroChamber Plus spacer for patients who find it difficult to synchronise aerosol actuation with inhalation.
MIMS recently published a table to help healthcare professionals compare the carbon footprints of asthma and COPD inhalers, and has also introduced a leaf symbol to highlight dry-powder and soft-mist inhalers, which have significantly lower carbon footprints than pMDIs.